Daniel Levy is a Cardiology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
788 Franklin Ave
Valley Stream, NY 115801502
Telephone
516-561-7500Registry record last updated 31 Oct 2013.
Clinical trials
- Extracellular RNAs in Relation to Cardiometabolic Risk
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
- RNA Sequencing in the Framingham Heart Study Third Generation Cohort Exam 2
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Program year20251 payment
- Althera Pharmaceuticals LLCProgram year20221 payment
- Intuity Medical IncProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
76.1%Beta blocker18.3%Metoprolol Succinate65%Carvedilol13%Metoprolol Tartrate12%Atenolol10%Part D≥85 patientsStatin17.5%Atorvastatin Calcium56%Rosuvastatin Calcium30%Simvastatin9%Pravastatin Sodium5%Part D<11 patients+ 13 more classes in this area
Blood & clotting
16.9%Factor Xa inhibitor12.2%Eliquis51%Xarelto49%Part D≥42 patientsP2Y12 inhibitor2.4%Clopidogrel100%Part D≥15 patients+ 1 more class in this area
Metabolism & gastrointestinal
5.4%SGLT2 inhibitor2%Jardiance73%Farxiga27%Part D<11 patientsProton pump inhibitor1.2%Pantoprazole Sodium100%Part D≥11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”